Document is current
Any future updates will be listed below
-
Authors
Pieniążek, Małgorzata https://orcid.org/0000-0001-5864-0877
Polakiewicz-Gilowska, Anna
Las-Jankowska, Manuela
Wronowicz, Jakub https://orcid.org/0000-0002-1454-2068
Jarząb, Michał
Łacko, Aleksandra
Püsküllüoğlu, Mirosława https://orcid.org/0000-0002-2647-9625
- License Information
-
More Information
Article History
Received: 25 July 2025
Accepted: 15 September 2025
First Online: 27 September 2025
Declarations
:
: The authors declare no competing interests.
: This research was approved by the ethical committees of the Maria Skłodowska-Curie National Research Institute of Oncology in Poland, including the Warsaw Branch (approval number 21/2024, issued on February 22, 2024) and the Kraków Branch (approval number 2/2023, issued on April 18, 2023). All activities involving human participants adhered to the ethical guidelines established by the institutional review board, the principles of the 1964 Helsinki Declaration, and subsequent updates or equivalent ethical frameworks. Before initiating SG treatment under the national reimbursement program, all patients provided informed consent following institutional protocols. The ethical committee concluded that additional informed consent was not necessary for the retrospective data collection. All procedures complied with applicable ethical guidelines and regulations.
